BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 35154089)

  • 1. Dominant Antiviral CD8
    Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
    Front Immunol; 2022; 13():680559. PubMed ID: 35154089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus.
    Dasari V; Smith C; Zhong J; Scott G; Rawlinson W; Khanna R
    J Gen Virol; 2011 May; 92(Pt 5):1021-1031. PubMed ID: 21307228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
    Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
    Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity.
    Dasari V; Smith C; Schuessler A; Zhong J; Khanna R
    Hum Vaccin Immunother; 2014; 10(4):1064-77. PubMed ID: 24463331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice.
    Huang C; Wang H; Wu S; Chang H; Liu L; Peng B; Fang F; Chen Z
    Virol J; 2014 Jun; 11():104. PubMed ID: 24898886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.
    Abel K; Strelow L; Yue Y; Eberhardt MK; Schmidt KA; Barry PA
    Vaccine; 2008 Nov; 26(47):6013-25. PubMed ID: 18760319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
    Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
    Front Immunol; 2021; 12():694588. PubMed ID: 34489940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.
    Panagioti E; Redeker A; van Duikeren S; Franken KL; Drijfhout JW; van der Burg SH; Arens R
    PLoS Pathog; 2016 Sep; 12(9):e1005895. PubMed ID: 27637068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gB co-immunization with GP96 enhances pulmonary-resident CD8 T cells and exerts a long-term defence against MCMV pneumonitis.
    Guo B; Xu P; Chai D; Cao L; Liu L; Song T; Hu S; Chen Y; Yan X; Xu T
    J Cell Mol Med; 2020 Dec; 24(24):14426-14440. PubMed ID: 33155438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
    Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
    Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.